Tag
Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.
Aficamten significantly improves diastolic function and cardiac structure in symptomatic nonobstructive hypertrophic cardiomyopathy, indicating benefits beyond outflow tract gradient reduction.
The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten
The FOREST-HCM long-term study confirms aficamten’s efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.
The MAPLE-HCM trial reveals that aficamten significantly outperforms metoprolol in reducing LVOT gradients and promoting favorable cardiac remodeling in patients with symptomatic obstructive HCM, signaling a potential shift in first-line th
The MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptom
A substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel, clinically relevant CPET metric that correlates with cardiac hemodynamics, predicts heart failure outcomes, and improves significantly with aficamten treatment in patients
This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offerin
A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).
This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the
Aficamten significantly improves exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM), demonstrating robust efficacy and safety in both mildly and severely symptomatic patients.
Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.
